Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Web alert

W M Sikov, B M Said

    Current Oncology Reports
    |June 16, 2001
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metabolomics-guided Mechanisms of Mesenchymal Stromal Cell and Exosome Therapies in Chronic Diseases.

    Stem cell reviews and reports·2026
    Same author

    Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okines and N. Turner.

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.

    Breast cancer research and treatment·2021
    Same author

    SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

    Breast cancer research and treatment·2016
    Same author

    Locally advanced breast cancer.

    Current treatment options in oncology·2002
    Same journal

    Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

    Current oncology reports·2026
    Same journal

    Anti-PD-1 Combinations: Triplets and Beyond.

    Current oncology reports·2026
    Same journal

    Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

    Current oncology reports·2026
    Same journal

    Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

    Current oncology reports·2026
    Same journal

    Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

    Current oncology reports·2026
    Same journal

    Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

    Current oncology reports·2026
    See all related articles